Shots:

• Regenxbio to receive $370M up front in addition to ~$1.38B as development- regulatory and commercial milestones along with royalties on net sales of RGX-314 outside the US. The transaction is expected to close at the end of 2021
• Regenxbio will be responsible for the manufacturing- clinical development & commercial supply for the therapy in the US. AbbVie will lead the clinical development and commercialization of RGX-314 globally
• Additionally- the companies will equally share profits from net sales of RGX-314 in the US. The therapy is currently being evaluated for wet AMD which is currently in pivotal trial and for DR in two P-II clinical trials by utilizing subretinal & suprachoroidal delivery respectively

  | Ref: Abbvie | Image: abbvie